INmune Bio (NASDAQ:INMB) is a clinical-stage immunology company based in San Diego, California, focused on developing novel therapies that harness the innate immune system to treat cancer and neurodegenerative diseases. Originally founded in 2010 and rebranded as INmune Bio in 2016, the company seeks to address unmet medical needs by targeting specific components of the body’s early-stage immune response. Through a combination of proprietary decoy receptor technology and cell-based immunotherapies, INmune Bio is advancing a pipeline designed to modulate inflammation, activate natural killer (NK) cells and neutralize harmful cytokines without compromising overall immune function.
At the core of INmune Bio’s pipeline is XPro1595, a selectively engineered inhibitor of soluble tumor necrosis factor (TNF) that aims to reduce chronic inflammation while preserving the beneficial actions of transmembrane TNF. XPro1595 is under investigation in multiple Phase 1 and Phase 2 studies for indications that include Alzheimer’s disease, glioblastoma and other inflammation-driven disorders. Complementing XPro1595 is INKmune, a proprietary platform that primes healthy donor NK cells ex vivo for infusion into patients with hematologic malignancies, enhancing their ability to recognize and destroy cancer cells. The company also maintains preclinical programs exploring additional decoy receptors and cytokine modulators for viral and fibrotic diseases.
INmune Bio conducts clinical trials and research collaborations across North America, Europe and Australia, partnering with academic institutions, contract research organizations and industry groups to accelerate patient access. The company’s global reach extends to specialized trial sites in major medical centers, enabling expedited enrollment and data collection for its lead candidates. By leveraging a lean operational model and strategic alliances, INmune Bio strives to bring first-in-class and best-in-class therapies from discovery through regulatory review with an emphasis on safety, efficacy and manufacturing scalability.
Led by President and Chief Executive Officer Brian P. Crowley, INmune Bio’s leadership team combines decades of experience in biopharmaceutical development, immunology research and commercialization. The board of directors and scientific advisory board feature experts in oncology, neurology and translational medicine. As INmune Bio advances its clinical programs, the company remains committed to expanding its therapeutic platform, exploring new indications, and forging partnerships that can enhance patient outcomes and deliver value to stakeholders in the rapidly evolving field of innate immuno-oncology and neuroinflammation.
